Research NewsAIDS Research

HIV Experts vs. Sequencers in Patent Race

See allHide authors and affiliations

Science  28 Feb 1997:
Vol. 275, Issue 5304, pp. 1263
DOI: 10.1126/science.275.5304.1263

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Half a dozen groups are vying for priority on CCR5—the receptor HIV uses to enter cells early in an infection—and many are filing patents. But these competitors may themselves be surprised to learn that a company that was not directly involved in these HIV studies—Human Genome Sciences of Rockville, Maryland—appears to have beaten everyone to the patent office.